Gilson Pauline, Merlin Jean-Louis, Harlé Alexandre
Service de Biologie Moléculaire des Tumeurs, Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN-Université de Lorraine, 6 avenue de Bourgogne CS 30519, 54519 Vandœuvre-lès-Nancy CEDEX, France.
Cancers (Basel). 2021 Mar 24;13(7):1491. doi: 10.3390/cancers13071491.
Microsatellite instability (MSI) is a molecular scar resulting from a defective mismatch repair system (dMMR) and associated with various malignancies. MSI tumours are characterized by the accumulation of mutations throughout the genome and particularly clustered in highly repetitive microsatellite (MS) regions. MSI/dMMR status is routinely assessed in solid tumours for the initial screening of Lynch syndrome, the evaluation of cancer prognosis, and treatment decision-making. Currently, pentaplex PCR-based methods and MMR immunohistochemistry on tumour tissue samples are the standard diagnostic methods for MSI/dMMR. Other tissue methods such as next-generation sequencing or real-time PCR-based systems have emerged and represent viable alternatives to standard MSI testing in specific settings. The evolution of the standard molecular techniques has offered the opportunity to extend MSI determination to liquid biopsy based on the analysis of cell-free DNA (cfDNA) in plasma. This review aims at synthetizing the standard and emerging techniques used on tumour tissue samples for MSI/dMMR determination. We also provide insights into the MSI molecular techniques compatible with liquid biopsy and the potential clinical consequences for patients with solid cancers.
微卫星不稳定性(MSI)是由错配修复系统缺陷(dMMR)导致的分子印记,与多种恶性肿瘤相关。MSI肿瘤的特征是全基因组突变积累,尤其集中在高度重复的微卫星(MS)区域。在实体瘤中,常规评估MSI/dMMR状态用于林奇综合征的初步筛查、癌症预后评估及治疗决策。目前,基于五重PCR的方法和肿瘤组织样本的错配修复免疫组化是MSI/dMMR的标准诊断方法。其他组织检测方法,如下一代测序或基于实时PCR的系统已经出现,并在特定情况下代表了标准MSI检测的可行替代方案。标准分子技术的发展为基于血浆中游离DNA(cfDNA)分析将MSI检测扩展到液体活检提供了机会。本综述旨在综合用于肿瘤组织样本中MSI/dMMR检测的标准技术和新兴技术。我们还深入探讨了与液体活检兼容的MSI分子技术以及实体癌患者的潜在临床后果。